BRIEF-TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint

Reuters07-01

July 1 (Reuters) - TRACON Pharmaceuticals Inc :

* TRACON PHARMACEUTICALS ANNOUNCES TERMINATION OF ENVASARC TRIAL AND WILL EXPLORE STRATEGIC ALTERNATIVES LEVERAGING ITS IN-HOUSE PRODUCT DEVELOPMENT PLATFORM

* TRACON PHARMACEUTICALS INC - TO FOCUS ON EXPLORING STRATEGIC ALTERNATIVES

* TRACON PHARMACEUTICALS INC - ENVASARC TRIAL ORR IS 5%, DOES NOT MEET 11% ENDPOINT

* TRACON PHARMACEUTICALS INC - TO REDUCE CASH BURN IMMEDIATELY

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2448721915?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-01 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2448721915","market":"us","top_or_hot":-1,"title":"BRIEF-TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint","media":"Reuters","content":"<html><body><p>July 1 (Reuters) - TRACON Pharmaceuticals Inc   :</p><p>   * TRACON PHARMACEUTICALS ANNOUNCES TERMINATION OF ENVASARC TRIAL AND WILL EXPLORE STRATEGIC ALTERNATIVES LEVERAGING ITS IN-HOUSE PRODUCT DEVELOPMENT PLATFORM</p><p>   * TRACON PHARMACEUTICALS INC - TO FOCUS ON EXPLORING STRATEGIC ALTERNATIVES</p><p>   * TRACON PHARMACEUTICALS INC - ENVASARC TRIAL ORR IS 5%, DOES NOT MEET 11% ENDPOINT</p><p>   * TRACON PHARMACEUTICALS INC - TO REDUCE CASH BURN IMMEDIATELY</p><p>Source text for Eikon:    Further company coverage:   </p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-TRACON Pharmaceuticals Says ENVASARC Trial ORR Is 5%, Does Not Meet 11% Endpoint\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-01 22:07 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1><strong>Reuters</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>July 1 (Reuters) - TRACON Pharmaceuticals Inc   :   * TRACON PHARMACEUTICALS ANNOUNCES TERMINATION OF ENVASARC TRIAL AND WILL EXPLORE STRATEGIC ALTERNATIVES LEVERAGING ITS IN-HOUSE PRODUCT DEVELOPMENT...</p>\n\n<a href=\"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TCON","symbol_name":"TRACON制药","start_time":0,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","article_id":"2448721915","we_media_id":"1036604489","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2448721915","pubTimestamp":1719842869,"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"summary":"July 1  - TRACON Pharmaceuticals Inc   :   * TRACON PHARMACEUTICALS ANNOUNCES TERMINATION OF ENVASARC TRIAL AND WILL EXPLORE STRATEGIC ALTERNATIVES LEVERAGING ITS IN-HOUSE PRODUCT DEVELOPMENT PLATFORM   * TRACON PHARMACEUTICALS INC - TO FOCUS ON EXPLORING STRATEGIC ALTERNATIVES   * TRACON PHARMACEUTICALS INC - ENVASARC TRIAL ORR IS 5%, DOES NOT MEET 11% ENDPOINT   * TRACON PHARMACEUTICALS INC - TO REDUCE CASH BURN IMMEDIATELYSource text for Eikon:    Further company coverage:    ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TCON":"TRACON制药","BK4139":"生物科技"},"translate_title":"简介-TRACON Pharmaceuticals表示ENVASARC试验ORR为5%，未达到11%的终点","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TCON":0.9},"content_text":"July 1 (Reuters) - TRACON Pharmaceuticals Inc   :   * TRACON PHARMACEUTICALS ANNOUNCES TERMINATION OF ENVASARC TRIAL AND WILL EXPLORE STRATEGIC ALTERNATIVES LEVERAGING ITS IN-HOUSE PRODUCT DEVELOPMENT PLATFORM   * TRACON PHARMACEUTICALS INC - TO FOCUS ON EXPLORING STRATEGIC ALTERNATIVES   * TRACON PHARMACEUTICALS INC - ENVASARC TRIAL ORR IS 5%, DOES NOT MEET 11% ENDPOINT   * TRACON PHARMACEUTICALS INC - TO REDUCE CASH BURN IMMEDIATELYSource text for Eikon:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2448721915"}